Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (557)	3/7/2005 4:36:46 PM
From: Ian@SI	Read Replies (1) of 946

It's an interesting and relatively short call. Several times, during the call as well as the Q&A thereafter, Bianco mentioned the highly statistically significant Xyo vs Pac survival superiourity. While the arms were balanced in terms of symptoms, it sounded as if the Xyo arm got some of the sickest patients - i.e. a larger number with multiple symptoms correlated with early death. Neither of these statements make a lot of sense to me. I don't understand how the Cox regression can be highly stat sig when the Log isn't. My assumption is that both are looking at survival. And I don't understand how both arms could be balanced in terms of the specific systems on an overall basis, but then not balanced in terms of the individuals assigned to the arm????? I completely indecisive re walking away or picking up some more shares at today's 1/2 off sale price. I'll probably sit for at least a few days before moving one way or the other. ... or not at all. :-(

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next